GFM
ELVN icon

GF Fund Management’s Enliven Therapeutics ELVN Stock Holding History

GF Fund Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.8K Sell
1,258
-75
-6% -$3.18K ﹤0.01% 368
2026
Q1 		$52.3K Buy
1,333
+168
+14% +$4.65K ﹤0.01% 393
2025
Q4 		$17.9K Sell
1,165
-109
-9% -$2.17K ﹤0.01% 519
2025
Q3 		$26.1K Buy
1,274
+23
+2% +$464 ﹤0.01% 459
2025
Q2 		$25.1K Hold
1,251
– – ﹤0.01% 477
2025
Q1 		$24.6K Buy
1,251
+225
+22% +$4.84K ﹤0.01% 479
2024
Q4 		$23.1K Buy
+1,026
New +$26.6K ﹤0.01% 460

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

GF Fund Management's ELVN Position: Q2 2026 in Review

GF Fund Management reduced its Enliven Therapeutics (ELVN) stake by 5.6% in Q2 2026, selling an estimated $3.18K and leaving 1,258 shares worth $63.8K. The position accounts for ﹤0.01% of the portfolio, ranked #368.

GF Fund Management first reported a position in ELVN in Q4 2024 and has held it in 7 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • GF Fund Management held 1,258 shares of Enliven Therapeutics worth $63.8K as of Q2 2026.
  • GF Fund Management sold 75 Enliven Therapeutics shares in Q2 2026, an estimated $3.18K.
  • Enliven Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #368 holding.
  • GF Fund Management first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.